ArticleJournal of comparative effectiveness research2026
Tralokinumab as a cost-saving treatment option for adults and adolescents with moderate-to-severe atopic dermatitis enrolled in US health insurance plans: a budget impact analysis.
Reece Grindley et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.